 Home > Medical News > Latest Medical News > STSA-1005 injection, a wholly-owned subsidiary of Shutaishen, obtained clinical trial approval from the U.S. FDA

STSA-1005 injection, a wholly-owned subsidiary of Shutaishen, obtained clinical trial approval from the U.S. FDA

 Last Update: 2021-11-05
 Source: Internet
 Author: User

Tags

fda regulate cosmetics

pci construction company

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On September 7, Stadson BioPharma Inc.
announced that its wholly-owned subsidiary, Staidson BioPharma Inc.
(California Biotech Co.
, Ltd.
) (hereinafter referred to as “Sureth California” or the “Company”) has received American Food and Drugs.
The FDA's notification email agrees that STSA-1005 injection will be used for the treatment of severe COVID-19 in clinical trials for the treatment of severe COVID-19 indications
.

Granulocyte-macrophage colony stimulating factor (GM-CSF) is a hematopoietic growth factor that stimulates the survival of granulocytes and monocytes by binding to the GM-CSF receptor (GM-CSFR or GMR) on the cell membrane.
Proliferation and activation, GMR is composed of specific ligand binding to the α chain (GM-CSFRα/GMRα) and signal transduction β chain (GM-CSFRβ/GMRβ)
.

STSA-1005 specifically binds to human GMRα and blocks its interaction with the ligand GM-CSF, thereby negatively regulating the innate immune response

STSA-1005 injection is independently developed by the company's wholly-owned subsidiary Stadson BioPharma Inc.

This new drug clinical trial license is the first clinical trial license for STSA-1005 injection in the world

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.